Linsidomine
From Wikipedia, the free encyclopedia
Linsidomine
|
|
Systematic (IUPAC) name | |
3-Morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine | |
Identifiers | |
CAS number | ? |
ATC code | C01 |
PubChem | |
Chemical data | |
Formula | C6H10N4O2 |
Mol. mass | 170.17 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Linsidomine is a vasodilator. Linsidomine (SIN-1) is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation ). Linsidomine injection at a dose of 1 mg produces usable erection in about 70% of patients and full erection in up to 50% of patients . Linsidomine does not appear to be associated with priapism .
|